Navigation Links
Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
Date:5/9/2011

ed March 31, 2011 and 2010, respectively.  General and administrative expenses were $2.8 million and $5.1 million in the quarters ended March 31, 2011 and 2010, respectively.  Expenses in 2010 included a one-time, non-cash charge of $1.1 million related to Alexza entering into a sublease agreement for a portion of one of its Mountain View facilities.

In connection with the acquisition of Symphony Allegro, Inc. in August 2009, Alexza is obligated to pay the former Symphony Allegro stockholders certain percentages of cash payments that may be generated from collaboration transactions for AZ-004, AZ-002 (Staccato alprazolam) or AZ-104 (Staccato loxapine, low-dose).  The Company records this obligation as a contingent liability and updates the liability each quarter.  Alexza did not record a non-operating gain or loss during the first quarter of 2011 as compared to a non-operating loss of $0.7 million in the quarter ended March 31, 2010.  Gains and losses incurred reflect Alexza's change in the estimated probability-weighted cash flows from AZ-004 and the estimated timing of receipt of such cash flows.

Conference Call Information

To access the conference call via the Web, please go to the Investor Relations tab at www.alexza.com.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PVNFWTCCE.  A replay of the call will be available for two weeks following the event.  

To access the live conference call via phone, dial 888-713-4214.  International callers may access the live call by dialing 617-213-4866.  The reference number to enter the ca
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexza to Present at the MDB Bright Lights Conference 2011
2. Alexza Prices $16.1 Million Registered Direct Offering
3. Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
4. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
5. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
6. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
7. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
8. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
9. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
10. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
11. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... März 2015  Die National Association of ... 2015 an Zulassungsanträge für Domainnamen mit der ... Seit dem Start des .Pharmacy Top-Level Domain- ... .pharmacy-Domainnamen zugelassen, die für die vorherigen, begrenzten ... Die NABP startete .pharmacy TLD, um Verbrauchern ...
(Date:3/26/2015)... profiled MJ Freeway , a business software company for ... Did It," which features companies with unique paths to success. ... illustrates how two tech entrepreneurs from Telluride, Colorado ... industry. Writer ... Jessica Billingsley used their experience in the technology ...
(Date:3/26/2015)... a loved relative suffering from cancer - and you ... too expensive. The Austrian Centre of Industrial Biotechnology (acib) ... costs of highly valued drugs significantly. ... pathogens or cancer cells. Therapeutic antibodies are used as ... diseases such as multiple sclerosis. According to "bccresearch.com" the ...
Breaking Medicine Technology:Alle abgebenden Apotheken berechtigt, um ab dem 1. April 2015 .Pharmacy-Domainnamen zu beantragen 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2World's First Method for Continuous Purification of Valuable Antibodies 2
... American Academy ... of Dermatology, FREEPORT, N.Y., Feb. ... diols (BMTds) to reduce,collagenese MMP-1 secretion and increase collagen production is dependent,on ... Session at the 66th Annual Meeting of the American Academy of,Dermatology in ...
... Provides Update on DARA Program,s Ongoing Phase 2a ... ... PCOP ), an innovator in the discovery and development of novel,small ... compound from its internal CCR1 discovery,program. PS031291 is a potent and ...
Cached Medicine Technology:AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling 2Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development 2Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development 3Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development 4
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... than $11.3 billion in 2014, according to an ... , The Annapolis-based healthcare real estate (HRE) data ... board members and two new Gold-Level Partners: Harrison ... Investment Services. , MOB transactions still going strong, ...
(Date:3/26/2015)... 2015 Pacific Medical LLC, the leader ... be featured on Innovations with Ed Begley Jr, which ... The episode will repeat on local cable channels ... Pacific Medical home page at: http://www.pacificmedicalsupply.com . ... is reassuring to trust the integrity of the medical ...
(Date:3/26/2015)... On March 5, 2015, Portland Trail ... for the season with a torn Achilles tendon in ... Blazers were competing against Dallas, and was confirmed via ... Silva, M.D., who has treated many professional athletes, voiced ... could be prevented. , "Part of the problem ...
(Date:3/26/2015)... In the key developed markets, the hypertension market value ... to decrease through 2020 at a negative CAGR (0.9%) to ... to 2017 at a 2.6% CAGR and a decline thereafter. ... surging penetration of fixed-dose combination drugs like Azor, Amturnide, Exforge ... and Tekamlo), a hike in the prevalence population to 190 ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
Breaking Medicine News(10 mins):Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 2Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 3Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 4Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3
... they are admitted to hospital may be one way to ... today’s BMJ. ,Recent data published by the Health ... 7,000 inpatients have MRSA infections and more than 50,000 inpatients ... of C difficile rose by 5.5% in 2006, whereas MRSA ...
... by blocking the lifesaving effects of aspirin//, a new study ... monstrous," Michael Farkouh, director of clinical trials at Mount Sinai ... ,“Ibuprofen is relatively safe except when we give it ... Farkouh says. "But when given with aspirin, we do we ...
... couple of months, 100,000 doses of the country's first vaccine ... developed it has found no takers //and the expiry date ... year that the High Security Animal Disease Laboratory (HSADL) here ... about 100,000 doses of the vaccine, each costing just 27 ...
... mammograms are more likely to interpret a benign growth ... and experience," and CAD systems do not help detect ... systems use complex algorithms to identify "suspicious" areas of ... which cost $50,000 to $175,000, were approved by FDA ...
... The Food and Drug Administration (FDA) today warned consumers ... Chews and Dog Chews manufactured// and distributed by T.W. ... have the potential to be contaminated with Salmonella, which ... if there is cross contamination, in people, especially children, ...
... Foundation on Wednesday announced that it will spend $500 ... address childhood obesity//, particularly targeting minority children, who are ... ,Nearly 25 million children under age 18 are considered ... medical expenses, according to the foundation. ,The ...
Cached Medicine News:Health News:Ibuprofen Risky for Heart Patients? 2Health News:100,000 Bird Flu Vaccine Doses to Be Destroyed 2
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
Medicine Products: